Urolithin A for Women's Health: Optimising Longevity in 2026

Urolithin A offers a promising pathway for women to enhance healthspan, particularly through mitochondrial support and muscle preservation, with considerations for hormonal stages.

# Urolithin A for Women's Health: Optimising Longevity in 2026

Urolithin A (UA), a postbiotic derived from ellagitannins found in pomegranates and other berries, has garnered significant attention in the longevity sphere. Its mechanism of action, primarily the induction of mitophagy – the selective clearance of damaged mitochondria – and stimulation of mitochondrial biogenesis, positions it as a compelling agent for cellular rejuvenation. While much of the foundational research initially spanned both sexes, a growing body of evidence, alongside physiological nuances, highlights specific considerations and potential benefits of Urolithin A for women. As we look towards 2026, understanding these specific applications becomes paramount for health optimisation.

Women's physiology, marked by distinct hormonal cycles, reproductive stages, and differing patterns of age-related decline, presents a unique context for evaluating longevity interventions. From reproductive prime through perimenopause and postmenopause, metabolic and musculoskeletal health undergoes significant shifts. Urolithin A, by targeting cellular energy production and muscle integrity, stands to offer a meaningful adjunctive strategy. This analysis delves into the science behind /supplements/urolithin-a for women, examining its evidence, benefits, risks, and practical considerations, all whilst acknowledging the often-overlooked nuances of female-specific health parameters.

The Unique Mitochondrial Landscape in Women

Mitochondria, often termed the 'powerhouses of the cell', play a critical role in cellular energy production and overall vitality. Their health is inextricably linked to virtually every aspect of our physiological functioning, from muscle performance to cognitive acuity. In women, mitochondrial function and cellular metabolism are significantly influenced by sex hormones, particularly oestrogen. Oestrogen is known to have protective effects on mitochondria, influencing their biogenesis, antioxidant defences, and metabolic efficiency. This protective effect diminishes significantly during perimenopause and postmenopause, leading to a decline in mitochondrial health that contributes to many age-related conditions prevalent in women, including sarcopenia, metabolic dysfunction, and cardiovascular disease risk.

Urolithin A's ability to induce mitophagy and support mitochondrial biogenesis therefore offers a strategic advantage. By helping cells clear out dysfunctional mitochondria and produce new, healthy ones, UA could potentially buffer some of the mitochondrial decline associated with lower oestrogen levels. This is not merely an theoretical benefit; preclinical models have shown that UA can improve mitochondrial respiratory capacity and reduce oxidative stress, parameters that are often compromised in an ageing female metabolism. For instance, a study published in *Nature Metabolism* (DOI: 10.1038/s42255-019-0073-4) showcased UA's ability to enhance muscle function and extend lifespan in *C. elegans* and improve muscle bioenergetics in rodents, irrespective of sex, but the underlying mechanisms hold particular relevance for hormone-mediated metabolic shifts in women. We’ve seen in reader cohorts how vital supporting mitochondrial optimization can be, especially for those experiencing age-related fatigue.

Muscle Health and Sarcopenia: A Female Perspective

Sarcopenia, the age-related loss of muscle mass, strength, and function, is a major concern for both men and women, but its progression and impact can differ significantly. Women tend to have lower peak muscle mass than men, making them more susceptible to the detrimental effects of even modest muscle loss. Oestrogen withdrawal at menopause accelerates muscle protein degradation and hinders muscle protein synthesis, contributing to a more rapid decline in muscle mass and strength. This is reflected in metrics like DEXA lean mass and grip strength, which often see a steeper decline post-menopause.

Urolithin A has shown promise in combating sarcopenia by directly enhancing muscle mitochondrial function. A seminal human clinical trial, published in *JAMA Network Open* (DOI: 10.1001/jamanetworkopen.2022.31682), demonstrated that daily supplementation with UA improved muscle endurance and reduced fatigue in older adults, irrespective of sex. While the trial was not female-specific, the mechanism of improved mitochondrial bioenergetics and expression of mitochondrial-related genes is directly applicable to the challenges women face. In another study, 1 gram of Urolithin A daily for four months improved leg muscle endurance and walking distance in healthy elderly individuals, indicating a functional benefit for mobility – a key aspect of healthspan for women. These improvements are critical for maintaining independence and quality of life as women age. Our editorial take is that UA could be a valuable tool in muscle preservation 50+, particularly when combined with resistance training.

Hormonal Cycles, Menopause, and Metabolic Health

The female hormonal landscape is dynamic, with fluctuations across the menstrual cycle, pregnancy, and crucially, the dramatic shifts of perimenopause and menopause. These hormonal changes profoundly impact metabolic health, increasing susceptibility to insulin resistance, altered lipid profiles, and weight gain. Oestrogen directly influences glucose uptake and insulin sensitivity, meaning its decline can lead to higher fasting insulin levels and increased risk of type 2 diabetes.

While direct studies on Urolithin A's interaction with female hormones are limited, its broad effects on mitochondrial health and systemic metabolism are highly relevant. By enhancing mitochondrial function, UA can improve cellular energy utilisation, which can indirectly support better glucose regulation. This effect could be particularly beneficial during perimenopause and postmenopause when metabolic flexibility often declines. Improved mitochondrial efficiency can also impact cellular stress responses, potentially modulating inflammation which is often exacerbated during hormonal transitions. However, there is no direct evidence to suggest Urolithin A can replace or mimic hormonal therapies. It should be seen as a complementary strategy to support overall metabolic resilience, a key component of glucose control.

Evidence Quality and Dosing for Women

The current body of evidence for Urolithin A, while growing, is still largely based on preclinical studies and initial human clinical trials that often include mixed-sex populations or do not specifically stratify for sex. This means that while the core mechanisms of action are well-established (Grade A/B evidence for general mitochondrial health and muscle function), female-specific trial data regarding optimal dosing, efficacy across different hormonal stages, and long-term safety are considered Grade C. We need more dedicated research focusing solely on women to move this to a higher grade.

Typical efficacious doses used in human trials range from 250 mg to 1000 mg per day. The 500 mg and 1000 mg doses have shown consistent benefits in muscle endurance and mitochondrial biomarkers. There is currently no evidence to suggest that women require a different dose than men based on body weight or hormonal status. However, individual responses can vary. As with any supplement, starting with a lower dose (e.g., 250 mg) and gradually increasing while monitoring subjective and objective markers, potentially through a biomarker insights tool, is a prudent approach. Biomarkers like VO₂max, grip strength, and DEXA lean mass can help track progress.

Risks, Contraindications, and Practical Considerations

Urolithin A is generally well-tolerated in human studies, with few reported side effects. Mild gastrointestinal discomfort has been noted in some individuals, particularly at higher doses. However, specific contraindications for women warrant careful consideration. Due to the lack of research on pregnant or breastfeeding women, Urolithin A should be avoided during these periods. The potential interactions with hormonal therapies, such as hormone replacement therapy (HRT), are also not fully understood. Women undergoing HRT should consult their healthcare provider before initiating UA supplementation. Similarly, women with pre-existing medical conditions, especially those related to metabolism or kidney function, should seek medical advice.

It's important to remember that the quality of Urolithin A supplements can vary widely. Sourcing from reputable manufacturers that provide third-party testing for purity and potency is crucial. While Urolithin A is available in the UK, its status as a novel food ingredient means regulatory oversight can be complex. Always check product claims carefully. Remember, when discussing any supplement, especially those touching on cellular pathways, consulting a healthcare professional is always advised. Please read our /legal/disclaimer before considering any new supplement protocol.

### Can Urolithin A Affect the Menstrual Cycle?

Currently, there is no scientific evidence to suggest that Urolithin A directly impacts the menstrual cycle. Its primary mechanisms relate to cellular mitochondrial function, not direct hormonal modulation. However, systemic improvements in metabolic health and inflammation could, theoretically, have secondary effects on overall well-being which *might* indirectly influence cycle regularity if underlying metabolic dysfunction was previously present. This is speculative, and direct causality has not been established. Women experiencing irregular cycles or other menstrual concerns should always consult a GP or gynaecologist.

### The Future of Urolithin A and Women's Health

As research progresses, we anticipate more dedicated studies focusing on Urolithin A's impact across different stages of women's lives. Future trials could explore its role in supporting fertility, ameliorating specific menopausal symptoms beyond muscle and metabolic health, or even its potential synergistic effects with other longevity compounds or interventions. The growing interest in personalised medicine and sex-specific health will undoubtedly drive further investigation into how compounds like Urolithin A can be optimally integrated into women's health strategies for enhanced healthspan and quality of life.

For now, Urolithin A represents a promising, evidence-backed strategy for women seeking to bolster their cellular health, maintain muscle mass, and support metabolic function, particularly as they navigate the shifts associated with ageing and menopause. Its focus on foundational mitochondrial health makes it a compelling consideration for proactive longevity planning.

Bottom Line

For women focused on preserving muscle function, supporting mitochondrial health, and enhancing metabolic resilience, especially through perimenopause and beyond, Urolithin A is unequivocally worth considering. Its evidence for improving muscle endurance and mitochondrial biomarkers is compelling (Grade A/B), and these benefits are highly relevant to age-related decline in women. However, women who are pregnant, breastfeeding, or on HRT should exercise caution and consult a healthcare professional due to limited specific data (Grade C evidence for these populations). For the majority of healthy women aiming to optimise their healthspan, incorporating 500-1000 mg of a high-quality Urolithin A supplement daily, alongside a balanced diet and regular exercise, represents a well-justified investment in cellular longevity. Skip if you're seeking a quick fix for hormonal imbalances; it's a foundational cellular support, not a hormonal modulator.